The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.
David Neal Franz
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Other Remuneration - Novartis
Christopher Kingswood
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Other Remuneration - Novartis
Sergiusz Jozwiak
Honoraria - Novartis
Klemens Budde
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Expert Testimony - Novartis
Elena Belousova
No relevant relationships to disclose
Steven Sparagana
Consultant or Advisory Role - Novartis
Honoraria - Novartis
B. A. Zonnenberg
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Michael Frost
Honoraria - Novartis
Research Funding - Novartis
Gaurav D. Shah
Employment or Leadership Position - Novartis
Jeremie Lebrec
Consultant or Advisory Role - Novartis
James Ford
Employment or Leadership Position - Novartis
Creton Kalfoglou
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
David Chen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
John Bissler
Honoraria - Novartis
Research Funding - Novartis